Tibet Rhodiola Pharmaceutical Holding Co. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was CNY 906.94 million compared to CNY 656.14 million a year ago.

Revenue was CNY 906.94 million compared to CNY 656.14 million a year ago. Net income was CNY 303.2 million compared to CNY 174.67 million a year ago. Basic earnings per share from continuing operations was CNY 1.22 compared to CNY 0.7 a year ago.

Diluted earnings per share from continuing operations was CNY 1.22 compared to CNY 0.7 a year ago.